Zoonotic Disease Treatment Global Market Report 2024

The zoonotic disease treatment market size has grown strongly in recent years. It will grow from $37.2 billion in 2023 to $39.71 billion in 2024 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to increased surveillance and reporting, the emergence of major zoonotic outbreaks, urbanization and habitat encroachment, globalization and increased travel and public awareness and education.

The zoonotic disease treatment market size is expected to see strong growth in the next few years. It will grow to $52.26 billion in 2028 at a compound annual growth rate (CAGR) of 7.1%. The anticipated expansion during the forecast period is a result of factors such as climate change and environmental conditions, government and international financial support, advancements in medical technology, supportive regulations with streamlined approvals, and collaborative efforts in research and development. Key trends expected in the forecast period encompass the creation of broad-spectrum antivirals, enhancement of global health infrastructure, progress in diagnostic technology, growth in vaccine development platforms, and an emphasis on preventive measures.

The escalating demand for animal proteins is projected to drive the expansion of the zoonotic disease treatment market in the future. Animal proteins, derived from sources such as meat, dairy, eggs, and fish, encompass all essential amino acids crucial for human health. The heightened demand for animal proteins is attributed to factors such as increasing global population, rising income levels, urbanization, and growing recognition of the nutritional advantages of animal-based foods. Zoonotic disease treatments play a crucial role in managing diseases associated with animal proteins, elucidating transmission pathways, developing effective therapies, and implementing preventive measures to mitigate public health risks. For example, as per a report jointly published by the Organization for Economic Co-operation and Development (OECD), a France-based intergovernmental organization, and the Food and Agriculture Organization, an Italy-based specialized agency, global meat protein consumption is expected to surge by 14% by 2030, with the availability of protein from various meat sources projected to increase, including beef by 5.9%, pork by 13.1%, poultry by 17.8%, and sheep meat by 15.7%. Consequently, the heightened demand for animal proteins is fueling the expansion of the zoonotic disease treatment market.

Leading companies in the zoonotic disease treatment market prioritize the development of innovative products, such as the tick-borne encephalitis (TBE) vaccine, to meet the increasing demand for effective prevention and control of zoonotic diseases. The TBE vaccine serves as a preventive measure against the tick-borne encephalitis virus, transmitted to humans through tick bites. It stimulates the immune system to generate antibodies against the TBE virus, thereby reducing the risk of contracting the disease. For example, in August 2021, Pfizer Inc., a US-based biopharmaceutical company, announced the approval of TICOVAC by the U.S. Food and Drug Administration (FDA). TICOVAC stands as the sole FDA-approved vaccine designed to protect adults and children in the United States from the TBE virus, particularly beneficial for individuals residing in or traveling to TBE-endemic regions.

In May 2022, Ceva Santé Animale, a veterinary pharmaceutical company headquartered in France, purchased Artemis Technologies Inc. for an undisclosed sum. This strategic acquisition bolsters Ceva's current rabies portfolio and extensive proficiency in manufacturing oral rabies vaccines and conducting rabies vaccination campaigns throughout Europe and other territories. Artemis Technologies Inc., based in Canada, specializes in supplying vaccines for zoonotic diseases.

Major companies operating in the zoonotic disease treatment market are Pfizer Inc., Johnson & Johnson Services Inc., Merck And Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis International AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Zoetis Inc., Boehringer Ingelheim International GmbH, Elanco Animal Health Incorporated, IDEXX Laboretories Inc., Hikma Pharmaceuticals PLC., Ceva Santé Animale, Vir Biotechnology Inc., Virbac, Vetoquinol S.A., BioCryst Pharmaceuticals Inc, Heska Corporation.

North America was the largest region in the zoonotic disease treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the zoonotic disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the zoonotic disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Treatment for zoonotic diseases encompasses medical interventions and therapies designed to diagnose, manage, and prevent illnesses caused by pathogens transmitted between animals and humans. This treatment regimen typically combines medication, vaccination, hygiene protocols, and control measures to minimize transmission and alleviate the impact of these infections on both animal and human communities.

The primary diseases addressed in zoonotic disease treatment include rabies, tuberculosis, malaria, leishmaniasis, Ebola virus disease, and others. Rabies, for instance, is a viral illness characterized by acute inflammation of the brain in humans and other mammals, commonly transmitted through the bite of an infected animal. Zoonotic disease treatment encompasses various drug classes such as anti-fungal, anti-bacterial, antibiotics, and others, targeting diverse agents such as bacteria, viruses, nematodes, rodents, ticks, and others. Administration routes comprise oral, topical, and others, with distribution occurring through channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others.

The zoonotic disease treatment market research report is one of a series of new reports that provides zoonotic disease treatment market statistics, including zoonotic disease treatment industry global market size, regional shares, competitors with a zoonotic disease treatment market share, detailed zoonotic disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the zoonotic disease treatment industry. This zoonotic disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The zoonotic disease treatment market consists of revenues earned by entities by providing services such as vaccinations, antimicrobial therapy, supportive care, and vector control. The market value includes the value of related goods sold by the service provider or included within the service offering. The zoonotic disease treatment market also includes sales of diagnostic kits, antimicrobial medications (antiparasitic, immunomodulators), and vector control products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.